Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334906 · ClinicalTrials.gov registry record · Phase 4
Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT00334906 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 75 participants.
The verdict
NCT00334906, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the progression of disease using volumetric MRI techniques and cognitive outcome measures in patients with moderate dementia of the Alzheimer's type treated with open-label memantine.
Interventions
- DRUG memantine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334906
The ClinicalTrials.gov registry entry for NCT00334906 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which memantine HCl is the first listed.
NCT00334906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00334906 about?
NCT00334906 is a clinical study titled "Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)". The purpose of this study is to characterize the progression of disease using volumetric MRI techniques and cognitive outcome measures in patients with moderate dementia of the Alzheimer's type treated with open-label memantine.
What is the current status of trial NCT00334906?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2005-07.
What interventions are being tested in trial NCT00334906?
The interventions under investigation include: memantine HCl (DRUG).
Who is sponsoring clinical trial NCT00334906?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.